The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
PPARγ2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells
Open accessAbstract
Rosiglitazone (Rosi), a member of the thiazolidinedione class of drugs used to treat type 2 diabetes, activates the adipocyte‐specific transcription factor peroxisome proliferator‐activated receptor gamma (PPARγ). This activation causes bone loss in animals and humans, at least in part due to suppression of osteoblast differentiation from marrow mesenchymal stem cells (MSC). In order to identify mechanisms by which PPARγ2 suppresses osteoblastogenesis and promotes adipogenesis in MSC, we have analyzed the PPARγ2 transcriptome in response to Rosi. A total of 4,252 transcriptional changes resulted when Rosi (1 µM) was applied to the U‐33 marrow stromal cell line stably transfected with PPARγ2 (U‐33/γ2) as compared to non‐induced U‐33/γ2 cells. Differences between U‐33/γ2 and U‐33 cells stably transfected with empty vector (U‐33/c) comprised 7,928 transcriptional changes, independent of Rosi. Cell type‐, time‐ and treatment‐specific gene clustering uncovered distinct patterns of PPARγ2 transcriptional control of MSC lineage commitment. The earliest changes accompanying Rosi activation of PPARγ2 included effects on Wnt, TGFβ/BMP and G‐protein signaling activities, as well as sustained induction of adipocyte‐specific gene expression and lipid metabolism. While suppression of osteoblast phenotype is initiated by a diminished expression of osteoblast‐specific signaling pathways, induction of the adipocyte phenotype is initiated by adipocyte‐specific transcriptional regulators. This indicates that distinct mechanisms govern the repression of osteogenesis and the stimulation of adipogenesis. The co‐expression patterns found here indicate that PPARγ2 has a dominant role in controlling osteoblast differentiation and suggests numerous gene‐gene interactions that could lead to the identification of a “master” regulatory scheme directing this process. J. Cell. Biochem. 106: 232–246, 2009. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844 · cited 3×
“…such as Wisp1, BMP4, Plk2, and Fosl2 (Fra-2) [Abe et al., 2000; McCauley et al., 2001; Ma et al., 2003; French et al., 2004], as well as Socs5, Ccl2 and RANKL, cytokines involved in osteoblast communication with hematopoietic environment [Boyce and Xing, 2008; O’Shea and Murray, 2008].”
BackgroundRosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Meta-analysis of primary target genes of peroxisome proliferator-activated receptors
Heinäniemi, M., Uski, J. O., Degenhardt, T., & Carlberg, C. (2007) · Genome Biology · doi:10.1186/gb-2007-8-7-r147 · Cited by 71
Cited by
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy
Järveläinen, H., Sainio, A., Koulu, M., Wight, T. N., & Penttinen, R. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001289 · Cited by 566
Inflamm-aging of hematopoiesis, hematopoietic stem cells, and the bone marrow microenvironment
Kovtonyuk, L. V., Fritsch, K., Feng, X., Manz, M. G., & Takizawa, H. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00502 · Cited by 371
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis
Kawai, M., & Rosen, C. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.155 · Cited by 323
Self-citationTseng, P.-C., Hou, S.-M., Chen, R.-J., Peng, H.-W., Hsieh, C.-F., Kuo, M.-L., & Yen, M.-L. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.460 · Cited by 291
Changes in primary lymphoid organs with aging
Chinn, I. K., Blackburn, C. C., Manley, N. R., & Sempowski, G. D. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.04.005 · Cited by 282
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
New insights into osteoporosis: the bone–fat connection
Kawai, M., de Paula, F. J. A., & Rosen, C. J. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02564.x · Cited by 273
Self-citationChen, J., Crawford, R., Chen, C., & Xiao, Y. (2013) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2012.0672 · Cited by 270
Sadie-Van Gijsen, H., Hough, F. S., & Ferris, W. F. (2013) · Bone · doi:10.1016/j.bone.2013.06.016 · Cited by 48
Metadata
- Authors
- Shockley, K. R., Lazarenko, O. P., Czernik, P. J., Rosen, C. J., Churchill, G. A., & Lecka‐Czernik, B.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2008-12-29
- Volume
- 106
- Issue
- 2
- Pages
- 232-246
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2005778832
- Cited by
- 169
- References
- 4
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.